Clinical and biomarker changes in Alzheimer's disease [1]

New England Journal of Medicine

Volumn 367, Issue 21, 2012, Pages 2050-2052

  Laske, Christoph ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; BLOOD ANALYSIS; CLINICAL ASSESSMENT; COGNITION; DIAGNOSTIC TEST; HUMAN; LETTER; MEMORY DISORDER; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; EPIDEMIOLOGY; GENE MUTATION; PATHOGENESIS; RISK BENEFIT ANALYSIS; CEREBROSPINAL FLUID; FEMALE; MALE; METABOLISM; NOTE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CEREBROSPINAL FLUID; FEMALE; HUMANS; MALE;

EID: 84869478624     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1211767     Document Type: Letter

References (5)

1. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795-804. [Erratum, N Engl J Med 2012;367:780.]
2. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28.
3. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30:1026-36.
4. Wilson RS, Arnold SE, Schneider JA, Boyle PA, Buchman AS, Bennett DA. Olfactory impairment in presymptomatic Alzheimer's disease. Ann N Y Acad Sci 2009;1170:730-5.
5. Jessen F, Wiese B, Bachmann C, et al. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry 2010;67:414-22.